Rao AG, Ancliff PJ. Juvenile myelomonocytic leukaemia – an update. MDIP 2008; 2(3): 12

Myeloproliferative Disorders in practice

Reference list

Rao AG, Ancliff PJ. Juvenile myelomonocytic leukaemia – an update. MDIP 2008; 2(3): 12–15.

1. Hasle H, Niemeyer CM, Chessells JM et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277–282.

2. Passmore SJ, Chessells JM, Kempski H et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758–767.

3. Niemeyer CM, Arico M, Basso G et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89: 3534–3543.

4. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925–929.

5. Tanaka M, Takahashi Y, Xu Y et al. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by (3)H-thymidine assay. Leuk Res 2008; 32: 1036–1042.

6. Kotecha N, Flores NJ, Irish JM et al. A novel assay for juvenile myelomonocytic leukaemia based on aberrant signalling networks measured via phospho-specific flow cytometry reduces diagnosis time from weeks to days. Blood 2007; 110: 168a.

7. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90: 479–488.

8. Privitera E, Schiro R, Longoni D et al. Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. Blood 1995; 86: 323–328.

9. Castro-Malaspina H, Schaison G, Passe S et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer 1984; 54: 675–686.

10. Owen G, Lewis IJ, Morgan M, Robinson A, Stevens RF. Prognostic factors in juvenile chronic granulocytic leukaemia. Br J Cancer Suppl 1992; 18: S68–S71.

11. Pinkel D. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998; 91: 365–367.

12. Manabe A, Yoshimasu T, Ebihara Y et al. Viral infections in juvenile myelomonocytic leukemia: prevalence and clinical implications. J Pediatr Hematol Oncol 2004; 26: 636–641.

13. Janik-Moszant A, Barc-Czarnecka M, van der Burg M et al. Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child. Leuk Res 2008; 32: 181–184.

14. Cooper LJ, Shannon KM, Loken MR et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 2000; 96: 2310–2313.

15. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994; 84: 3435–3439.

16. Side LE, Emanuel PD, Taylor B et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267–272.

17. Savage P, Frenck R, Paderanga D, Emperor J, Shannon KM. Parental origins of chromosome 7 loss in childhood monosomy 7 syndrome. Leukemia 1994; 8: 485–489.

18. Flotho C, Steinemann D, Mullighan CG et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 2007; 26: 5816–5821.

19. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3: 203–209.

20. Tartaglia M, Mehler EL, Goldberg R et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465–468.

21. Tartaglia M, Niemeyer CM, Fragale A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.

22. Loh ML, Vattikuti S, Schubbert S et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103: 2325–2331.

23. Kratz CP, Niemeyer CM, Castleberry RP et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005; 106: 2183–2185.

24. Schubbert S, Lieuw K, Rowe SL et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005; 106: 311–317.

25. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005; 6: 45–68.

26. Flotho C, Valcamonica S, Mach-Pascual S et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32–37.

27. Zebisch A, Czernilofsky AP, Keri G et al. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 2007; 14: 601–623.

28. Matsuda K, Shimada A, Yoshida N et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007; 109: 5477–5480.

29. Flotho C, Kratz CP, Bergstrasser E et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood 2008; 111: 966–967; author reply 967–968.

30. Zecca M, Bergamaschi G, Kratz C et al. JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia 2007; 21: 367–369.

31. Kratz CP, Niemeyer CM, Thomas C et al. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia 2007; 21: 1108–1109.

32. de Vries AC, Stam RW, Kratz CP et al. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. Haematologica 2007; 92: 1574–1575.

33. de Vries AC, Stam RW, Schneider P et al. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. Haematologica 2007; 92: 1557–1560.

34. Passmore SJ, Hann IM, Stiller CA et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85: 1742–1750.

35. Castleberry RP, Emanuel PD, Zuckerman KS et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994; 331: 1680–1684.

36. Castleberry RP, Loh ML, Jayaprakash N et al. Phase II window study of the farnesyl transferase inhibitor R115777 (Zarnestra) in untreated juvenile myelomonocytic leukemia. Blood 2005; 106: 727a.

37. Shimada H, Shima H, Shimasaki N et al. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol 2005; 16: 1400.

38. Braun BS, Shannon K. Targeting ras in myeloid leukemias. Clin Cancer Res 2008; 14: 2249–2252.

39. Wahlstrom AM, Cutts BA, Karlsson C et al. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood 2007; 109: 763–768.

40. Metzner A, Horstmann MA, Fehse B et al. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Gene Ther 2007; 14: 699–703.

41. Bergstraesser E, Hasle H, Rogge T et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2007; 49: 629–633.

42. Archambeault S, Flores NJ, Yoshimi A et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 2008; 111: 1124–1127.

Published by Hayward Medical Communications